Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel

To determine the relationship between chemotherapy-induced peripheral neuropathy (CIPN) severity and centrosomal protein 72 (CEP72) genotype in young adults receiving paclitaxel or vincristine. 50 young adults aged 21-39 years who were expected to receive a cumulative dose of at least 7 mg vincristine or 700 mg/m2 paclitaxel for the treatment of cancer were recruited from Dana-Farber Cancer Institute. Participants completed a CIPN assessment tool and provided a blood sample before the first infusion. Participants completed the assessment tool at two additional time points. DNA was genotyped for CEP72 rs924607. CIPN scores were compared between those with the TT versus the CC or CT genotype over time using linear mixed-effects models. Young adults receiving vincristine with the TT CEP72 genotype experienced higher CIPN severity by the final time point, but the differences were not statistically significant (p > 0.05). Future work to validate biomarkers like CEP72 may allow clinicians to identify patients who may benefit from altered chemotherapy dosages relative to CIPN risk.